CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAF(P261A) and CRAF(P207S). To our knowledge, both mutations are novel in lung cancer and CRAF(P261A) has not been previously reported in cancer. Expression...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncogene
Asıl Yazarlar: Noeparast, Amir, Giron, Philippe, Noor, Alfiah, Bahadur Shahi, Rajendra, De Brakeleer, Sylvia, Eggermont, Carolien, Vandenplas, Hugo, Boeckx, Bram, Lambrechts, Diether, De Grève, Jacques, Teugels, Erik
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2019
Konular:
Brief Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6756226/
https://ncbi.nlm.nih.gov/pubmed/31285551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-019-0866-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller